These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 1992306

  • 1. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB, Foley J, Nelson P, Goodman WG.
    N Engl J Med; 1991 Feb 21; 324(8):527-31. PubMed ID: 1992306
    [Abstract] [Full Text] [Related]

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP.
    Clin Nephrol; 1996 Feb 21; 45(2):111-9. PubMed ID: 8846523
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 21; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J.
    N Engl J Med; 1986 Jul 17; 315(3):157-61. PubMed ID: 3724805
    [Abstract] [Full Text] [Related]

  • 5. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Jul 17; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 6. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D, Battegay M, Meier C, Lyrer A.
    Schweiz Med Wochenschr; 1990 Mar 03; 120(9):295-8. PubMed ID: 2315655
    [Abstract] [Full Text] [Related]

  • 7. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.
    Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN.
    J Pediatr; 1986 May 03; 108(5 Pt 1):767-70. PubMed ID: 3701525
    [Abstract] [Full Text] [Related]

  • 8. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI.
    Ter Arkh; 1997 May 03; 69(12):63-7. PubMed ID: 9503540
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A.
    Am J Kidney Dis; 1988 Dec 03; 12(6):487-91. PubMed ID: 3143260
    [Abstract] [Full Text] [Related]

  • 10. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study].
    Eichhorn M.
    Fortschr Med; 1989 Aug 10; 107(23):502-6. PubMed ID: 2670719
    [Abstract] [Full Text] [Related]

  • 11. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function.
    Lin JL, Leu ML.
    Nephrol Dial Transplant; 1996 Sep 10; 11(9):1891-3. PubMed ID: 8918652
    [No Abstract] [Full Text] [Related]

  • 12. Calcium carbonate as a phosphate binder in children on continuous ambulatory peritoneal dialysis and hemodialysis.
    Sieniawska M, Roszkowska-Blaim M, Weglarska J, Jabłczyńska A, Welc-Dobies J.
    Mater Med Pol; 1991 Sep 10; 23(3):203-8. PubMed ID: 1842716
    [Abstract] [Full Text] [Related]

  • 13. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE, Johnson CA.
    Clin Pharm; 1985 Sep 10; 4(4):434-9. PubMed ID: 3899471
    [Abstract] [Full Text] [Related]

  • 14. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH, Schäfer C, Schmitt H, Gladziwa U, Sieberth HG.
    Klin Wochenschr; 1991 Jan 22; 69(2):59-67. PubMed ID: 2027271
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J.
    Nephrol Dial Transplant; 1989 Jan 22; 4(2):105-9. PubMed ID: 2496350
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun 22; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 18. Autonomous hyperparathyroidism not associated with increased aluminum absorption.
    Mocan MZ, Mocan H, Fell GS, Junor BJ, Boyce BF.
    Isr J Med Sci; 1992 Jan 22; 28(1):24-6. PubMed ID: 1733894
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of calcium carbonate in children with chronic renal failure.
    Clark AG, Oner A, Ward G, Turner C, Rigden SP, Haycock GB, Chantler C.
    Nephrol Dial Transplant; 1989 Jan 22; 4(6):539-44. PubMed ID: 2507975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.